Search

Erwin W Gelfand

from Englewood, CO
Age ~83
Get Report
Also known as:
Ew W Gelfand, Irwin Gelfand
Phone and address:
4275 Bellaire Cir, Englewood, CO 80110
(303) 692-9074
Related to:
Marilyn H GelfandAdele Felfand, 79Lauren Gelfand, 50Allison Gelfand, 45Adele Gelfand, 79
Connected to:
Adelaide B Gelfand, 27Arthur S Gelfand, 88Brett Gelfand, 32Courtney A Gelfand, 34Edwin H Gelfand, 103Isaak A Gelfand, 85Rina R Gelfand, 50Morris F Gelfeld, 105Elina Gelfenboym, 47Mary A Gelfer, 73

Erwin Gelfand Phones & Addresses

  • 4275 Bellaire Cir, Englewood, CO 80110 (303) 692-9074
  • 4275 Bellaire St, Englewood, CO 80110
  • Frisco, CO
  • Fairfield, ID
  • Denver, CO
  • Tucson, AZ
  • Boulder, CO
  • Washington, DC

Work

Address: 1400 Jackson St, Denver, CO 80206 Specialities: Pediatrician

Education

School / High School: McGill University, Faculty of Medicine - Doctor of Medicine

Ranks

Certificate: American Board of Pediatrics Certification in Pediatrics

Professional Records

Medicine Doctors

Erwin Gelfand Photo 1

Erwin Gelfand, Denver CO

Work:
National Jewish Health
1400 Jackson St, Denver, CO 80206
Erwin Gelfand Photo 2

Erwin W Gelfand, Denver CO

View page
Specialties:
Pediatrician
Address:
1400 Jackson St, Denver, CO 80206
Education:
McGill University, Faculty of Medicine - Doctor of Medicine
Children's Hospital Boston - Fellowship - Immunology
Board certifications:
American Board of Pediatrics Certification in Pediatrics

License Records

Medical Doctor

Address:
1400 Jackson St, Denver, CO 80206
License #:
27997 - Active
Issued Date:
Jan 15, 1987
Renew Date:
May 1, 2015
Expiration Date:
Apr 30, 2017
Type:
Physician

Business Records

Name / Title
Company / Classification
Phones & Addresses
Erwin William Gelfand
Erwin Gelfand MD
Allergist · Pediatric Allergist · Pediatrician
1400 Jackson St, Denver, CO 80206
(877) 225-5654

Publications

Isbn (Books And Publications)

The Year Book of Allergy and Clinical Immunology 1994

View page
Author

Erwin Gelfand

ISBN #

0815172753

Us Patents

Regulation Of Cytokine Production In A Hematopoietic Cell

View page
US Patent:
6495331, Dec 17, 2002
Filed:
May 5, 1999
Appl. No.:
09/305720
Inventors:
Erwin W. Gelfand - Englewood CO
Gary L. Johnson - Boulder CO
Assignee:
National Jewish Center for Immunology and Respiratory Medicine - Denver CO
International Classification:
G01N 3353
US Classification:
435 72, 435 71, 424 851, 514 2
Abstract:
A method useful for regulating cytokine production by a hematopoietic cell by regulating an MEKK/JNKK-contingent signal transduction pathway in such a cell is disclosed. Methods of identifying compounds capable of specifically regulating an MEKK/JNKK-contingent signal transduction pathway in hematopoietic cells, a kit for identifying cytokine regulators, methods to treat diseases involving cytokine production, and cells useful in such methods are also set forth.

Method For The Production Of Conjugates And Uses Thereof For The Prevention And Treatment Of Allergic Reactions And Autoimmune Diseases

View page
US Patent:
6537519, Mar 25, 2003
Filed:
Jan 8, 2001
Appl. No.:
09/755132
Inventors:
Yves Borel - Vandoeuvres, CH
Werner Schlegel - Chancy, CH
Erwin Gelfand - Englewood CO
Assignee:
Aventis Behring GmbH - Marburg
International Classification:
A61K 5108
US Classification:
424 149, 424 153, 4241781, 4241791, 4242751, 4241941, 5303871, 5303911, 5303915, 5303919
Abstract:
The present invention relates to a method for the preparation of a conjugate comprising a first and a second polypeptide, said method comprising the steps of (a) incubating said first polypeptide in the presence of a heterobifunctional crosslinker comprising an N-hydroxylsuccinimide ester group and a maleimide group linked via a polyethylene oxide spacer; (b) removing excess heterobifunctional crosslinker; and (c) incubating the reaction product of step (b) with said second polypeptide, wherein said second polypeptide comprises at least one sulfhydryl group. Furthermore, the present invention relates to a conjugate obtainable by the method of the present invention. Also described is a pharmaceutical composition comprising the conjugate of the present invention and, optionally, a pharmaceutically acceptable carrier and/or diluent, and the use of the conjugate for the preparation of a pharmaceutical composition for preventing and/or treating an allergic disease or an autoimmune disease.

Modulation Of T Cells To Regulate Airway Hyperresponsiveness

View page
US Patent:
6737398, May 18, 2004
Filed:
Sep 28, 2000
Appl. No.:
09/672865
Inventors:
Erwin Gelfand - Englewood CO
Willi K. Born - Denver CO
Michael F. Lahn - Denver CO
Arihiko Kanehiro - Okayama, JP
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 3800
US Classification:
514 2, 514 21, 424 851
Abstract:
Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of T cells in a patient. Also disclosed are methods for identifying compounds hyperresponsiveness by modulating T cell action.

Method For Regulating Cell Growth And Assays Related Thereto

View page
US Patent:
7160681, Jan 9, 2007
Filed:
May 22, 2002
Appl. No.:
10/154272
Inventors:
Erwin W. Gelfand - Englewood CO, US
Joseph J. Lucas - Evergreen CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
C12Q 1/68
US Classification:
435 6, 435 723
Abstract:
Disclosed are methods for assessing tumor cell growth in a patient for the diagnosis, monitoring and/or staging of tumor development. The method include the identification of reduced cdk6 expression or biological activity as an indicator of increased cell growth in a cell sample. The methods further include the identification of compounds which regulate cdk6 and the use of such compounds in a method for the regulation of inappropriate cell growth.

Method For The Production Of Conjugates And Uses Thereof For The Prevention And Treatment Of Allergic Reactions And Autoimmune Diseases

View page
US Patent:
7306782, Dec 11, 2007
Filed:
Feb 14, 2003
Appl. No.:
10/366569
Inventors:
Yves Borel - Vandoeuvres, CH
Werner Schlegel - Chancy, CH
Erwin Gelfand - Englewood CO, US
Assignee:
Tolerogen Ltd - Geneva
International Classification:
A61K 51/10
A61K 39/35
A61K 39/395
C07K 16/46
C07K 17/06
US Classification:
424 119, 424 153, 4241781, 4241791, 4241941, 4242751, 5303911, 5303915, 5303919
Abstract:
The present invention relates to a method for the preparation of a conjugate comprising a first and a second polypeptide, said method comprising the steps of (a) incubating said first polypeptide in the presence of a heterobifunctional crosslinker comprising an N-hydroxylsuccinimide ester group and a maleimide group linked via a polyethylene oxide spacer; (b) removing excess heterobifunctional crosslinker; and (c) incubating the reaction product of step (b) with said second polypeptide, wherein said second polypeptide comprises at least one sulfhydryl group. Furthermore, the present invention relates to a conjugate obtainable by the method of the present invention. Also described is a pharmaceutical composition comprising the conjugate of the present invention and, optionally, a pharmaceutically acceptable carrier and/or diluent, and the use of the conjugate for the preparation of a pharmaceutical composition for preventing and/or treating an allergic disease or an autoimmune disease.

Modulation Of Gamma Delta T Cells To Regulate Airway Hyperresponsiveness

View page
US Patent:
7582300, Sep 1, 2009
Filed:
Mar 24, 2004
Appl. No.:
10/808846
Inventors:
Erwin Gelfand - Englewood CO, US
Willi K. Born - Denver CO, US
Michael F. Lahn - Denver CO, US
Arihiko Kanehiro - Okayama, JP
Assignee:
National Jewish Health - Denver CO
International Classification:
A01N 61/00
A61K 31/00
A61K 39/38
A61K 39/02
A61K 39/04
US Classification:
4241841, 4242341, 4242481, 4242821, 514 1
Abstract:
Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of γδ T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating γδ T cell action.

Methods Of Using Nucleic Acid Vector-Lipid Complexes

View page
US Patent:
7741300, Jun 22, 2010
Filed:
Dec 27, 2005
Appl. No.:
11/320019
Inventors:
Steven W. Dow - Littleton CO, US
Robyn E. Elmslie - Littleton CO, US
Jurgen Karl Johannes Schwarze - Witten, DE
Erwin W. Gelfand - Englewood CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 48/00
C12N 15/88
C12N 15/63
US Classification:
514 44R, 435458, 4353201
Abstract:
This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

Anti-Factor B Antibodies

View page
US Patent:
7999082, Aug 16, 2011
Filed:
Feb 10, 2005
Appl. No.:
11/057047
Inventors:
Vernon Michael Holers - Denver CO, US
Joshua M. Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin W. Gelfand - Englewood CO, US
Gary Steven Gilkeson - Charleston SC, US
Assignee:
National Jewish Medical and Research Center - Denver CO
MUSC Foundation for Research Development - Charleston SC
The Regents of the University of Coloraodo - Boulder CO
International Classification:
C07K 16/36
C07K 16/00
A61K 39/395
US Classification:
53038825, 5303871, 5303873, 5303881, 5303882, 4241301, 4241331, 4241411, 4241451, 4241581
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Control profile
Erwin W Gelfand from Englewood, CO, age ~83 Get Report